APA (7th ed.) Citation

Marth, C., Lorusso, D., Bidzinski, M., Salutari, V., Akıllı, H., Oaknin, A., . . . Makker, V. (2025). 1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. Annals of Oncology, 36, S748. https://doi.org/10.1016/j.annonc.2025.08.1760

Chicago Style (17th ed.) Citation

Marth, C., et al. "1124P Lenvatinib + Pembrolizumab (L + P) in Participants (Pts) with Advanced or Recurrent Endometrial Cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 Post-(neo)adjuvant Therapy Outcomes." Annals of Oncology 36 (2025): S748. https://doi.org/10.1016/j.annonc.2025.08.1760.

MLA (9th ed.) Citation

Marth, C., et al. "1124P Lenvatinib + Pembrolizumab (L + P) in Participants (Pts) with Advanced or Recurrent Endometrial Cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 Post-(neo)adjuvant Therapy Outcomes." Annals of Oncology, vol. 36, 2025, p. S748, https://doi.org/10.1016/j.annonc.2025.08.1760.